{"success":true,"data":{"pressRelease":{"id":"166219","rtpr_id":"nBwQQwzma-20261012","ticker":"PODD","exchange":"NASDAQ","all_tickers":["PODD"],"title":"Insulet Announces Omnipod Discover Now Available in U.S.","author":"Business Wire","published_at":"2026-10-12T11:00:00.335Z","article_body":"Insulet Announces Omnipod Discover Now Available in U.S.\n\nWeb-based data platform turns Omnipod 5 data into clear, personalized insights\nfor users, caregivers, and healthcare professionals\n\nInsulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump\ntechnology\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.omnipod.com%2F&esheet=54620057&newsitemid=20261012734213&lan=en-US&anchor=tubeless+insulin+pump+technology&index=1&md5=14961b4e7568da17c012b894a3e5b81b)\nwith its Omnipod(®) brand of products, today announced the U.S. full market\nrelease of Omnipod Discover™, a web-based data platform designed for Omnipod\n5 users, their caregivers, and healthcare providers (HCPs). Omnipod Discover\nturns critical diabetes data into clear visualizations and personalized\ninsights, giving people with diabetes and their HCPs a shared understanding of\ntherapy patterns to make more informed diabetes management decisions.\n\n\"The future of diabetes care is not just about generating more data, it's\nabout making that data meaningful,” said Dr. Trang Ly, MBBS, FRACP, PhD,\nSenior Vice President and Chief Medical Officer at Insulet. “Omnipod\nDiscover simplifies data review for Omnipod 5 users and their healthcare\nproviders so they spend less time gathering information and more time\ncollaborating on diabetes management.\"\n\nWith Omnipod Discover, Omnipod 5 users get simple, personalized glucose and\ninsulin delivery reports sent directly to their smartphone weekly, so they\nknow where to focus their diabetes management efforts. Omnipod Discover also\nhelps HCPs make confident clinical recommendations from a concise report by\noverlaying a licensed Ambulatory Glucose Profile (AGP) with key adjustable\npump settings and bolus events.\n\nOmnipod Discover has already been adopted in the United States by more than\n15,000 Omnipod 5 users and over 1,800 healthcare professionals as part of\nInsulet's limited market release program in the U. S. It is also available to\nusers and HCPs in Spain, Australia, Saudi Arabia, Qatar, Kuwait, UAE, and\nIsrael.\n\n\"In today's AID (automated insulin delivery) era, clinicians need actionable\ninsights, not more data. Omnipod Discover brings key diabetes metrics and\ninsights together in a streamlined, easy-to-use workflow that supports\nclinical decision-making and patient conversations,” said Dr. Martin Sarkar,\nDO, ECNU, Endocrinologist at EndoCARE Diabetes & Wellness Center in\nFrederick, Maryland. “It also gives people with diabetes greater visibility\ninto their therapy, helping foster engagement and trust. Omnipod Discover is\nan important step toward a more connected diabetes ecosystem that supports\nboth providers and patients.\"\n\nIn June, Insulet presented Real-World Glycemic Outcomes(1) using the Omnipod\nDiscover platform at the American Diabetes Association’s Scientific Sessions\nin New Orleans, Louisiana. Use of Omnipod Discover was associated with\nimprovements in time in range (TIR), with 32% of users seeing a clinically\nmeaningful increase in TIR of 3% or more. These findings support the vital\nrole that user engagement with Omnipod Discover can play in diabetes\nself-management.\n\nThe platform is now available to all Omnipod 5 users nationwide, with\nhealthcare professionals able to enroll through onboarding and training\nprovided by their dedicated Omnipod sales representative.\n\nTo enroll in Omnipod Discover, Omnipod 5 users can log into PodderCentral\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.poddercentral.com&esheet=54620057&newsitemid=20261012734213&lan=en-US&anchor=PodderCentral&index=2&md5=adb89f53d35a6c4d21a733dde31a9efb)\nand follow the on-screen prompts. Healthcare professionals can visit our\nwebsite\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.omnipod.com%2Fhcp%2Fproducts%2Fomnipod-discover&esheet=54620057&newsitemid=20261012734213&lan=en-US&anchor=visit+our+website&index=3&md5=9e2995bd00365de945afa83f4e3aa73b)\nto learn more or contact their dedicated Omnipod sales representative.\n (1 )Mora, PF, et al. Real-World Glycemic Outcomes Using the Omnipod Discover                                                                                                                                                                                                              \n Data Management System. Diabetes 1 June 2026; 75 (Supplement 1): 2887–LB.                                                                                                                                                                                                                 \n https://doi.org/10.2337/db26-2887-LB                                                                                                                                                                                                                                                      \n (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fdoi.org%2F10.2337%2Fdb26-2887-LB&esheet=54620057&newsitemid=20261012734213&lan=en-US&anchor=https%3A%2F%2Fdoi.org%2F10.2337%2Fdb26-2887-LB&index=4&md5=5d341928b2057a1edc1b5eb61646b5e7)                               \n\n\nAbout Insulet Corporation:\n\nInsulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an\ninnovative medical device company dedicated to simplifying life for people\nwith diabetes and other conditions through its Omnipod product platform. The\nOmnipod Insulin Management System provides a unique alternative to traditional\ninsulin delivery methods. With its simple, wearable design, the tubeless\ndisposable Pod provides up to three days of non-stop insulin delivery, without\nthe need to see or handle a needle. Insulet’s flagship innovation, the\nOmnipod 5 Automated Insulin Delivery System, integrates with a continuous\nglucose monitor to manage blood sugar with no multiple daily injections, zero\nfingersticks, and can be controlled by a compatible personal smartphone in the\nU.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design\nof its Pod by tailoring its Omnipod technology platform for the delivery of\nnon-insulin subcutaneous drugs across other therapeutic areas. For more\ninformation, visit insulet.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.insulet.com%2F&esheet=54620057&newsitemid=20261012734213&lan=en-US&anchor=insulet.com&index=5&md5=5778d64316da288977e71e74380b080b)\nor omnipod.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.omnipod.com%2F&esheet=54620057&newsitemid=20261012734213&lan=en-US&anchor=omnipod.com&index=6&md5=782ac1133eebea94c0230c7b9f7ba724)\n.\n\n©2026 Insulet Corporation. Omnipod, Omnipod Discover and PodderCentral are\ntrademarks or registered trademarks of Insulet Corporation in the United\nStates of America and other various jurisdictions. All rights reserved.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261012734213/en/\n(https://www.businesswire.com/news/home/20261012734213/en/)\n\nInvestor Relations: \n\nClare Trachtman\n\nVice President, Investor Relations\n\nir@insulet.com (mailto:ir@insulet.com)\n\nMedia: \n\nJoan Campion\n\nVice President, External Communications\n\npr@insulet.com (mailto:pr@insulet.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBwQQwzma-20261012","title":"Insulet Announces Omnipod Discover Now Available in U.S.","author":"Business Wire","ticker":"PODD","created":"2026-10-12T11:00:00.335Z","tickers":["PODD"],"exchange":"NASDAQ","article_body":"Insulet Announces Omnipod Discover Now Available in U.S.\n\nWeb-based data platform turns Omnipod 5 data into clear, personalized insights\nfor users, caregivers, and healthcare professionals\n\nInsulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump\ntechnology\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.omnipod.com%2F&esheet=54620057&newsitemid=20261012734213&lan=en-US&anchor=tubeless+insulin+pump+technology&index=1&md5=14961b4e7568da17c012b894a3e5b81b)\nwith its Omnipod(®) brand of products, today announced the U.S. full market\nrelease of Omnipod Discover™, a web-based data platform designed for Omnipod\n5 users, their caregivers, and healthcare providers (HCPs). Omnipod Discover\nturns critical diabetes data into clear visualizations and personalized\ninsights, giving people with diabetes and their HCPs a shared understanding of\ntherapy patterns to make more informed diabetes management decisions.\n\n\"The future of diabetes care is not just about generating more data, it's\nabout making that data meaningful,” said Dr. Trang Ly, MBBS, FRACP, PhD,\nSenior Vice President and Chief Medical Officer at Insulet. “Omnipod\nDiscover simplifies data review for Omnipod 5 users and their healthcare\nproviders so they spend less time gathering information and more time\ncollaborating on diabetes management.\"\n\nWith Omnipod Discover, Omnipod 5 users get simple, personalized glucose and\ninsulin delivery reports sent directly to their smartphone weekly, so they\nknow where to focus their diabetes management efforts. Omnipod Discover also\nhelps HCPs make confident clinical recommendations from a concise report by\noverlaying a licensed Ambulatory Glucose Profile (AGP) with key adjustable\npump settings and bolus events.\n\nOmnipod Discover has already been adopted in the United States by more than\n15,000 Omnipod 5 users and over 1,800 healthcare professionals as part of\nInsulet's limited market release program in the U. S. It is also available to\nusers and HCPs in Spain, Australia, Saudi Arabia, Qatar, Kuwait, UAE, and\nIsrael.\n\n\"In today's AID (automated insulin delivery) era, clinicians need actionable\ninsights, not more data. Omnipod Discover brings key diabetes metrics and\ninsights together in a streamlined, easy-to-use workflow that supports\nclinical decision-making and patient conversations,” said Dr. Martin Sarkar,\nDO, ECNU, Endocrinologist at EndoCARE Diabetes & Wellness Center in\nFrederick, Maryland. “It also gives people with diabetes greater visibility\ninto their therapy, helping foster engagement and trust. Omnipod Discover is\nan important step toward a more connected diabetes ecosystem that supports\nboth providers and patients.\"\n\nIn June, Insulet presented Real-World Glycemic Outcomes(1) using the Omnipod\nDiscover platform at the American Diabetes Association’s Scientific Sessions\nin New Orleans, Louisiana. Use of Omnipod Discover was associated with\nimprovements in time in range (TIR), with 32% of users seeing a clinically\nmeaningful increase in TIR of 3% or more. These findings support the vital\nrole that user engagement with Omnipod Discover can play in diabetes\nself-management.\n\nThe platform is now available to all Omnipod 5 users nationwide, with\nhealthcare professionals able to enroll through onboarding and training\nprovided by their dedicated Omnipod sales representative.\n\nTo enroll in Omnipod Discover, Omnipod 5 users can log into PodderCentral\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.poddercentral.com&esheet=54620057&newsitemid=20261012734213&lan=en-US&anchor=PodderCentral&index=2&md5=adb89f53d35a6c4d21a733dde31a9efb)\nand follow the on-screen prompts. Healthcare professionals can visit our\nwebsite\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.omnipod.com%2Fhcp%2Fproducts%2Fomnipod-discover&esheet=54620057&newsitemid=20261012734213&lan=en-US&anchor=visit+our+website&index=3&md5=9e2995bd00365de945afa83f4e3aa73b)\nto learn more or contact their dedicated Omnipod sales representative.\n (1 )Mora, PF, et al. Real-World Glycemic Outcomes Using the Omnipod Discover                                                                                                                                                                                                              \n Data Management System. Diabetes 1 June 2026; 75 (Supplement 1): 2887–LB.                                                                                                                                                                                                                 \n https://doi.org/10.2337/db26-2887-LB                                                                                                                                                                                                                                                      \n (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fdoi.org%2F10.2337%2Fdb26-2887-LB&esheet=54620057&newsitemid=20261012734213&lan=en-US&anchor=https%3A%2F%2Fdoi.org%2F10.2337%2Fdb26-2887-LB&index=4&md5=5d341928b2057a1edc1b5eb61646b5e7)                               \n\n\nAbout Insulet Corporation:\n\nInsulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an\ninnovative medical device company dedicated to simplifying life for people\nwith diabetes and other conditions through its Omnipod product platform. The\nOmnipod Insulin Management System provides a unique alternative to traditional\ninsulin delivery methods. With its simple, wearable design, the tubeless\ndisposable Pod provides up to three days of non-stop insulin delivery, without\nthe need to see or handle a needle. Insulet’s flagship innovation, the\nOmnipod 5 Automated Insulin Delivery System, integrates with a continuous\nglucose monitor to manage blood sugar with no multiple daily injections, zero\nfingersticks, and can be controlled by a compatible personal smartphone in the\nU.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design\nof its Pod by tailoring its Omnipod technology platform for the delivery of\nnon-insulin subcutaneous drugs across other therapeutic areas. For more\ninformation, visit insulet.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.insulet.com%2F&esheet=54620057&newsitemid=20261012734213&lan=en-US&anchor=insulet.com&index=5&md5=5778d64316da288977e71e74380b080b)\nor omnipod.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.omnipod.com%2F&esheet=54620057&newsitemid=20261012734213&lan=en-US&anchor=omnipod.com&index=6&md5=782ac1133eebea94c0230c7b9f7ba724)\n.\n\n©2026 Insulet Corporation. Omnipod, Omnipod Discover and PodderCentral are\ntrademarks or registered trademarks of Insulet Corporation in the United\nStates of America and other various jurisdictions. All rights reserved.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261012734213/en/\n(https://www.businesswire.com/news/home/20261012734213/en/)\n\nInvestor Relations: \n\nClare Trachtman\n\nVice President, Investor Relations\n\nir@insulet.com (mailto:ir@insulet.com)\n\nMedia: \n\nJoan Campion\n\nVice President, External Communications\n\npr@insulet.com (mailto:pr@insulet.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-10-12T11:00:00.393006304Z","server_sent_at_ms":1791802800393},"received_at":"2026-10-12T11:00:00.494Z","source_url":"https://www.businesswire.com/news/home/20261012734213/en/"},"analysis":{"id":"154584","press_release_id":"166219","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":[],"eventType":"product_launch","narrative":"Insulet announced the full U.S. market release of Omnipod Discover, a web-based data platform that converts Omnipod 5 data into personalized insights for users, caregivers, and healthcare providers.\n\nThe platform was already adopted by more than 15,000 U.S. Omnipod 5 users and over 1,800 healthcare professionals during a limited market release, and is available in seven additional countries.\n\nReal-world data presented at the ADA Scientific Sessions showed 32% of users achieved a clinically meaningful time-in-range improvement of 3% or more, supporting the platform's role in engagement and therapy retention.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Software layer on Omnipod 5 goes nationwide -- engagement and retention play, not a near-term revenue driver."},"keyFigures":{"customDimensions":{"hcps_adopted_us":1800,"users_adopted_us":15000,"users_with_tir_improvement":"32% saw clinically meaningful TIR increase of 3% or more"}},"quotedText":"The future of diabetes care is not just about generating more data, it's about making that data meaningful","namedEntities":{"people":[{"name":"Dr. Trang Ly","role":"SVP and Chief Medical Officer, Insulet"},{"name":"Dr. Martin Sarkar","role":"Endocrinologist, EndoCARE Diabetes & Wellness Center"},{"name":"Clare Trachtman","role":"Vice President, Investor Relations"},{"name":"Joan Campion","role":"Vice President, External Communications"}],"products":["Omnipod Discover","Omnipod 5","PodderCentral","Omnipod Insulin Management System"],"companies":[{"name":"Insulet Corporation","ticker":"PODD","relationship":"filer"},{"name":"EndoCARE Diabetes & Wellness Center","relationship":"quoted clinician practice"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Full U.S. market release of a software/data platform that complements the existing Omnipod 5 franchise. It supports engagement and retention but adds no immediate revenue or regulatory milestone."},"tickerRelevance":{"others":[],"primary":"PODD"},"globalImportance":22,"audienceRelevance":35,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"large-cap-medtech","eventGravity":"complementary-software-launch","householdBrandBoost":"low","retailFavoriteBoost":"moderate"}},"event_type":"product_launch","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Insulet announced the full U.S. market release of Omnipod Discover, a web-based data platform that converts Omnipod 5 data into personalized insights for users, caregivers, and healthcare providers.\n\nThe platform was already adopted by more than 15,000 U.S. Omnipod 5 users and over 1,800 healthcare professionals during a limited market release, and is available in seven additional countries.\n\nReal-world data presented at the ADA Scientific Sessions showed 32% of users achieved a clinically meaningful time-in-range improvement of 3% or more, supporting the platform's role in engagement and therapy retention.","key_figures":{"customDimensions":{"hcps_adopted_us":1800,"users_adopted_us":15000,"users_with_tir_improvement":"32% saw clinically meaningful TIR increase of 3% or more"}},"named_entities":{"people":[{"name":"Dr. Trang Ly","role":"SVP and Chief Medical Officer, Insulet"},{"name":"Dr. Martin Sarkar","role":"Endocrinologist, EndoCARE Diabetes & Wellness Center"},{"name":"Clare Trachtman","role":"Vice President, Investor Relations"},{"name":"Joan Campion","role":"Vice President, External Communications"}],"products":["Omnipod Discover","Omnipod 5","PodderCentral","Omnipod Insulin Management System"],"companies":[{"name":"Insulet Corporation","ticker":"PODD","relationship":"filer"},{"name":"EndoCARE Diabetes & Wellness Center","relationship":"quoted clinician practice"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-12T11:00:05.662Z","global_importance":22,"audience_relevance":35,"importance_components":{"tickerTier":"large-cap-medtech","eventGravity":"complementary-software-launch","householdBrandBoost":"low","retailFavoriteBoost":"moderate"}},"durationMs":5142,"modelName":"glm-5.3-flashx"}}